Literature DB >> 29992216

Hierarchically stimuli-responsive nanovectors for improved tumor penetration and programed tumor therapy.

Junjie Liu1, Xingming Guo, Zhong Luo, Jixi Zhang, Menghuan Li, Kaiyong Cai.   

Abstract

Poor drug delivery to solid tumors remains a great challenge for effective antitumor therapy. Herein, multistage stimuli-responsive nanovectors based on hollow mesoporous silica nanoparticles (HMSNs) were prepared to avoid delivery barriers for improved penetration and programmed tumor therapy. The versatile nanosystem was constructed through electrostatic complexation between the functional HMSNs loaded with gemcitabine (GEM) and the small-sized platinum prodrug-conjugated poly(amidoamine) dendrimer (PAMAM-Pt). The HMSNs were functionalized with dimethylmaleic anhydride tethered chitosan oligosaccharide to endow the particles of HMSN-CS(DMA) with charge-reversal properties. The as-prepared nanosystem had a stable structure of size ∼130 nm at pH 7.4, which is beneficial for blood circulation and tumor vessel extravasation of nanocarriers. Once it reaches the tumor site, the nanosystem can dissociate into HMSN@GEM-CS (∼120 nm) and PAMAM-Pt dendrimer nanocarriers (∼5 nm) in response to the acidic tumor microenvironment because of the acid-mediated charge-reversal, then the HMSN@GEM can play the antitumor role in surface tumor tissues. The dissociated PAMAM-Pt showed excellent performance in tumor penetration, cell uptake and intracellular trafficking due to the small size and positive charge, which was supported by the study of three-dimensional multicellular spheroids in vitro. Finally, the active cisplatin was released from the PAMAM-Pt dendrimer under the intracellular reducing environment to kill cells in deep tumor tissues. The significant tumor suppression of this system in vivo was validated in the A549 tumor xenografted mouse model. Such a stimuli-responsive nanosystem that integrates simple preparation, biocompatibility, biodegradability and programmed tumor therapy manifests great potential for clinical trials.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29992216     DOI: 10.1039/c8nr02971g

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  5 in total

1.  Core-Shell Imidazoline-Functionalized Mesoporous Silica Superparamagnetic Hybrid Nanoparticles as a Potential Theranostic Agent for Controlled Delivery of Platinum(II) Compound.

Authors:  Mehdi Abedi; Samira Sadat Abolmaali; Mozhgan Abedanzadeh; Fatemeh Farjadian; Soliman Mohammadi Samani; Ali Mohammad Tamaddon
Journal:  Int J Nanomedicine       Date:  2020-04-20

2.  Targeted polymeric nanoparticles for drug delivery to hypoxic, triple-negative breast tumors.

Authors:  Babak Mamnoon; Jagadish Loganathan; Matthew I Confeld; Nimesha De Fonseka; Li Feng; Jamie Froberg; Yongki Choi; Daniel M Tuvin; Venkatachalem Sathish; Sanku Mallik
Journal:  ACS Appl Bio Mater       Date:  2020-12-23

Review 3.  Particle toxicology and health - where are we?

Authors:  Michael Riediker; Daniele Zink; Wolfgang Kreyling; Günter Oberdörster; Alison Elder; Uschi Graham; Iseult Lynch; Albert Duschl; Gaku Ichihara; Sahoko Ichihara; Takahiro Kobayashi; Naomi Hisanaga; Masakazu Umezawa; Tsun-Jen Cheng; Richard Handy; Mary Gulumian; Sally Tinkle; Flemming Cassee
Journal:  Part Fibre Toxicol       Date:  2019-04-23       Impact factor: 9.400

4.  Boosting cisplatin chemotherapy by nanomotor-enhanced tumor penetration and DNA adducts formation.

Authors:  Lihua Xu; Kaixiang Zhang; Xing Ma; Yingying Li; Yajie Jin; Chenglin Liang; Yong Wang; Wendi Duan; Hongling Zhang; Zhenzhong Zhang; Jinjin Shi; Junjie Liu; Yunlong Wang; Wentao Li
Journal:  J Nanobiotechnology       Date:  2022-09-29       Impact factor: 9.429

5.  A chitosan-based cascade-responsive drug delivery system for triple-negative breast cancer therapy.

Authors:  Shiwei Niu; Gareth R Williams; Jianrong Wu; Junzi Wu; Xuejing Zhang; Xia Chen; Shude Li; Jianlin Jiao; Li-Min Zhu
Journal:  J Nanobiotechnology       Date:  2019-09-10       Impact factor: 10.435

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.